PRODUCTS

 

 

RIZAPORT® oral soluble film’s administration method presents a potentially attractive therapeutic alternative for migraine patients, specifically those who suffer from dysphagia (difficulty swallowing)¹ and migraine-related nausea, which is estimated to affect approximately 80% of the total migraine patient population.

RIZAPORT® demonstrated bioequivalence to the reference listed drug Maxalt-MLT® (Merck & Co.) in a successful pivotal clinical trial. IntelGenx submitted a 505(b)(2) New Drug Application (NDA) for regulatory approval to the U.S. Food and Drug Administration (FDA), which has assigned a Prescription Drug User Fee Act (PDUFA) goal date for completion of the review of the RIZAPORT® NDA of March 26, 2020. In October 2018, the Spanish Agency of Medicines and Medical Devices (AEMPS) granted national marketing approval for RIZAPORT® for the treatment of acute migraines.
Global migraine sales are expected to grow to $8.7 billion by 2026, at a compound annual growth rate (CAGR) of 10.3%2.